Dr. Thomas Boyce, MD Surgery - Surgery of the Hand Medicare: Not Enrolled in Medicare Practice Location: 20131 44th Ave Ne, Lake Forest Park, WA 98155 Phone: 206-799-3234 |
News Archive
The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.
Vantage Benefits Administrators (VBA) is proud to announce the acquisition of the BISNet software and all its Intellectual Property from ClearBenefits, Inc. to strategically enhance our Unified Point of Service administration offerings. BISNet, Inc., a fully owned subsidiary of Vantage Benefits Administrators, will reemerge as a world class benefits enrollment and administration system provider on July 15, 2010.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Droplets emanating from a molecular "nano-tap" would behave very differently from those from a household tap 1 million times larger - researchers at the University of Warwick have found.
While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients' risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer.
› Verified 6 days ago